Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment

por Clemens, Pamela L., Yan, Xiaoyu, Lokhorst, Henk M., Lonial, Sagar, Losic, Nedjad, Khan, Imran, Jansson, Richard, Ahmadi, Tahamtan, Lantz, Kristen, Zhou, Honghui, Puchalski, Thomas, Xu, Xu Steven
Publicado 2016

Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma

por Yan, Xiaoyu, Clemens, Pamela L., Puchalski, Thomas, Lonial, Sagar, Lokhorst, Henk, Voorhees, Peter M., Usmani, Saad, Richardson, Paul G., Plesner, Torben, Liu, Kevin, Orlowski, Robert Z., Losic, Nedjad, Jansson, Richard, Ahmadi, Tahamtan, Lantz, Kristen, Ruixo, Juan Jose Perez, Zhou, Honghui, Xu, Xu Steven
Publicado 2017